JP5840857B2 - Composition for inducing cytotoxic T cells - Google Patents

Description

  The present invention relates to a composition for inducing cytotoxic T cells, a pharmaceutical composition containing cytotoxic T cells obtained by exposing the composition for inducing cytotoxic T cells, and a method for producing the pharmaceutical composition And about.

  In vivo, antigen-specific cytotoxic T cells (hereinafter also referred to as “CTL”) are induced by the interaction of hematopoietic stem cell-derived CD8-positive cells with dendritic cells. The interaction involves the association of a fragment of the antigen molecule with the HLA class I molecule on the surface of the dendritic cell and the TCR / CD3 / CD8 complex on the surface of the CD8 positive cell. As a result of the interaction, the CD8-positive cell specifically recognizes a cell in which an HLA class I molecule that matches the compatible type of the HLA class I molecule forms a complex with a fragment of the antigen molecule. Cell to attack. The interaction is also facilitated by the association of CD28 molecules on the surface of CD8 positive cells with CD80 / 86 molecules on the surface of dendritic cells.

  In the case of viral infection, cytotoxic T cells that specifically recognize viral antigens attack virally infected cells. In the case of tumor cells, cytotoxic T cells that recognize tumor-specific antigens attack the tumor cells. Therefore, in tumor immunotherapy, the problem is how to efficiently induce cytotoxic T cells.

  Advances in cytokine research have made it relatively easy to differentiate and proliferate CD8 positive cells, which are precursor cells of cytotoxic T cells, from hematopoietic stem cells such as cord blood, peripheral blood, and bone marrow. However, it is difficult to isolate and purify dendritic cells in large quantities from living organisms. Therefore, techniques for artificially mimicking the function of dendritic cells have been developed. An example of such an artificial antigen-presenting cell is a technique in which a cell such as fibroblast is transfected with a gene such as an HLA class I molecule, an antigen molecule, or a CD80 / 86 molecule to substitute for a dendritic cell. is there. In addition, a complex of an MHC class I molecule tetramer and an antigen peptide (hereinafter referred to as “antigen tetramer”) can bind to a plurality of T cell receptors on the same cell surface. In addition to detecting T cells recognizing (Non-patent document 1), it is also used for antigen-specific T cell activation (Non-patent document 2). Then, a fluorescence obtained by binding an antigen tetramer labeled with phycoerythrin (hereinafter referred to as “PE”) and an anti-CD28 antibody labeled with PE through a biotinylated anti-PE antibody and avidin. Labeled paramagnetic bead particles can induce cytotoxic T cells (Non-patent Document 3). Although this is not an organism, it is considered as a kind of artificial antigen-presenting cell.

  There is also a technique for stimulating CD8 positive cells instead of dendritic cells by binding antibodies against molecules expressed in CD8 positive cells to the surface of beads, microparticles, and the like. As a technique using such an immobilized antibody, anti-CD3 / CD28 beads are known in which an anti-CD3 antibody and an anti-CD28 antibody having agonist activity are bound to the same bead particle (Patent Document 1). Among the interactions that induce CTL, for the association between the fragment of the antigen molecule and the HLA class I molecule on the surface of the dendritic cell and the TCR / CD3 / CD8 complex on the surface of the CD8 positive cell, CD8 positive cells can be stimulated by using anti-CD3 antibodies with agonist activity instead of a complex of molecular fragments and HLA class I molecules on the surface of dendritic cells. In addition, regarding the association between the CD28 molecule on the surface of CD8 positive cells and the CD80 / 86 molecule on the surface of dendritic cells, an anti-CD28 antibody having agonist activity is used instead of the CD80 / 86 molecule on the surface of dendritic cells. By using it, CD8 positive cells can be stimulated. However, antigen-specific CTL induction is not possible with anti-CD3 / CD28 beads alone, and in order to induce antigen-specific CTL, it is necessary to use either an antigen-presenting cell derived from a living body or an artificial antigen-presenting cell in combination. It was.

International Publication No. WO2004 / 104185 Pamphlet

Altman, J. et al. D. Science, 274: 94 (1996). Daniels, M.M. A. And Jameson, S .; C. J. et al. Exp. Med. 191: 335 (2000) Oelke, M.M. Et al., Nature Medicine, 9: 619 (2003).

  However, creating conventional antigen-presenting cells or artificial antigen-presenting cells requires time and effort. Therefore, it is necessary to develop a new technique that can easily perform antigen-specific CTL induction for any antigen.

  The present invention provides a composition for inducing cytotoxic T cells, comprising an anti-CD28 antibody, a solid support on which the anti-CD28 antibody is immobilized, and a soluble peptide capable of binding to MHC class I molecules. .

  The composition for inducing cytotoxic T cells of the present invention may comprise an anti-CD28 antibody, a solid support on which the anti-CD28 antibody is immobilized, and a soluble peptide capable of binding to MHC class I molecules. .

  In the composition for inducing cytotoxic T cells of the present invention, the solid support may be a culture vessel used for cell culture containing the CD8 positive cells or a microbead.

  In the cytotoxic T cell-inducing composition of the present invention, the soluble peptide capable of binding to the MHC class I molecule is presented as an antigen by the patient's HLA-compatible HLA complex and recognized by the cytotoxic T cell. May be.

  The present invention provides a pharmaceutical composition for tumor treatment. The pharmaceutical composition for tumor treatment of the present invention comprises the composition for inducing cytotoxic T cells of the present invention, and the soluble peptide capable of binding to the MHC class I molecule is an amino acid sequence of a specific antigen protein of tumor cells. Including the portion, the cytotoxic T cells recognize the tumor cells.

  In the pharmaceutical composition for tumor treatment of the present invention, the specific antigen protein of the tumor cell may be WT-1.

  The present invention provides a pharmaceutical composition for treating viral diseases. The pharmaceutical composition for treating viral diseases of the present invention comprises the composition for inducing cytotoxic T cells of the present invention, wherein the soluble peptide capable of binding to the MHC class I molecule is an amino acid sequence of a virus-specific antigen protein. Including the portion, the cytotoxic T cells recognize the tumor cells.

  In the pharmaceutical composition for treating a viral disease of the present invention, the specific antigen protein of the virus may be a pp65 protein of cytomegalovirus.

  The present invention provides a pharmaceutical composition. The pharmaceutical composition of the present invention is obtained by exposing the composition for inducing cytotoxic T cells of the present invention to CD8 positive cells derived from hematopoietic stem cells, and recognizes a soluble peptide capable of binding to the MHC class I molecule. Includes cytotoxic T cells.

  In the pharmaceutical composition of the present invention, the hematopoietic stem cells are any stem cell-derived hematopoietic stem cell selected from the group consisting of embryonic stem cells, adult stem cells and induced pluripotent stem (iPS) cells, and cord blood-derived hematopoietic stem cells. The hematopoietic stem cells, peripheral blood-derived hematopoietic stem cells, and bone marrow blood-derived hematopoietic stem cells may be selected.

  The present invention provides a method for producing a pharmaceutical composition comprising cytotoxic T cells. The method for producing a pharmaceutical composition comprising cytotoxic T cells of the present invention comprises (1) any stem cell-derived one selected from the group consisting of embryonic stem cells, adult stem cells, and induced pluripotent stem (iPS) cells. CD8 positive cells are proliferated predominantly from at least one hematopoietic stem cell selected from the group consisting of hematopoietic stem cells, cord blood-derived hematopoietic stem cells, peripheral blood-derived hematopoietic stem cells, and bone marrow blood-derived hematopoietic stem cells. And (2) exposing the CD8 positive cell to the composition for inducing cytotoxic T cells according to claim 1; and (3) recognizing a soluble peptide capable of binding to the MHC class I molecule. Culturing cytotoxic T cells.

  In the method for producing a pharmaceutical composition containing cytotoxic T cells of the present invention, the soluble peptide capable of binding to the MHC class I molecule includes an amino acid sequence of human WT-1 protein or cytomegalovirus pp65 protein. There is a case.

  The present invention provides an immunotherapy comprising the step of transplanting a pharmaceutical composition comprising the cytotoxic T cells of the present invention.

  The immunotherapy of the present invention includes CD8 positive cells obtained by collecting hematopoietic stem cells including, but not limited to, peripheral blood and bone marrow of a patient, or CD8 differentiated and / or amplified from the obtained hematopoietic stem cells. It may include exposing the positive cells to the cytotoxic T cell-inducing composition of the present invention in vitro and reimplanting the induced cytotoxic T cells into a patient.

  In the immunotherapy of the present invention, CD8 positive cells differentiated from a patient's somatic cell-derived adult stem cell or a patient's somatic cell-derived induced pluripotent stem cell are induced in vitro in the cytotoxic T cell of the present invention. Exposing to the composition for use and reimplanting the induced cytotoxic T cells into the patient.

  Sources of the CD8 positive cells of the present invention may include tissues including but not limited to peripheral blood, bone marrow, lymph nodes and umbilical cord blood. It is preferable that the dendritic cell or its precursor cell of the present invention is prepared from peripheral blood. However, it may be prepared from hematopoietic stem cells generated from embryonic stem cells, adult stem cells and induced pluripotent stem (iPS) cells.

  In order for CD8 positive cells to be induced in cytotoxic T cells, simultaneously with stimulating CD28 on CD8 positive cells, a complex of MHC class I molecule and antigen epitope molecule and T cell receptor / CD3 / Antigen presentation by association with the CD8 complex needs to occur. According to the present invention, CD8 positive cells are induced in cytotoxic T cells using only the immobilized anti-CD28 antibody and soluble antigen peptide, and without using dendritic cells. Although the mechanism of action is not theoretically bound, the composition for inducing cytotoxic T cells of the present invention is assumed by assuming the involvement of cells expressing HLA class I molecules contained in the culture of CD8 positive cells. The mechanism of action can be rationally explained. FIG. 1 is a schematic diagram for explaining the mechanism of action of the present invention. Referring to FIG. 1, CD8 positive cell 1 is subjected to CTL induction by soluble peptide 2 and anti-CD28 antibody 4 immobilized on solid support 3 such as magnetic beads. Here, the anti-CD28 antibody 4 immobilized on the solid support 3 reacts with the CD28 molecule 5 on the CD8 positive cell 1, and the CD28 molecule 5 interacts with the CD80 / 86 on the dendritic cell. Stimulation is applied to CD8 positive cells 1. On the other hand, the soluble peptide 2 alone is not recognized by the T cell receptor / CD3 / CD8 complex 6 on the CD8 positive cell 1. However, when soluble peptide 2 binds to HLA class I molecule 7 on cell 8 expressing HLA class I molecule in the culture of said CD8 positive cell 1, the T cell receptor / CD3 / CD8 complex on CD8 positive cell 1 6 is presented as an antigen. Thus, cytotoxic T that recognizes soluble peptide 2 restricted by HLA class I molecule 7 can be obtained simply by adding soluble peptide 2 and anti-CD28 antibody immobilized on solid support 3 to CD8-positive cell 1. Cell 9 is derived from CD8 positive cell 1. According to the method of the present invention, it is possible to induce CTL against different types of antigens simply by replacing the soluble peptide. Moreover, CTL induction | guidance | derivation with respect to 2 types or 3 types or more of antigen can also be performed simultaneously.

  The soluble peptide capable of binding to the MHC class I molecule of the present invention may consist of the amino acid sequences listed in SEQ ID NOs: 1 to 5 in the sequence listing attached to the present specification. Soluble peptides that can bind to MHC class I molecules of the present invention are not limited to HLA-A restricted epitopes. It has been conventionally known that cytotoxic T cells specific to other antigens can be amplified in vitro and that clinical effects can be obtained by transplanting such cytotoxic T cells into a patient. For example, Godet, Y. et al. (Cancer Immunol. Immunother., 58: 271-280 (2009)) obtained cytotoxic T cells specific for HLA-B-restricted peptides derived from the cancer antigen tyrosinase specific for melanoma. Straathof, K.M. C. M.M. (Blood, 105: 1898-1904 (2005)), HLA-B restricted epitope of EB virus related antigen LMP2, HLA-B restricted epitope of EB virus related antigen EBNA1, HLA- of EB virus related antigen EBNA3. CTLs specific for B-restricted epitopes, HLA-B-restricted epitopes of EB virus-related antigen BZLF1, etc. were transplanted into EB virus-related nasopharyngeal cancer patients to obtain clinical effects. Walter, E .; A. (N. Engl. J. Med., 333: 1038-44 (1995)) received cytomegalovirus (CMV) -specific CTL after receiving bone marrow transplantation from a CMV-positive relative for leukemia treatment. A clinical effect was obtained by transplanting into a patient in which CMV was reactivated while being administered an immunosuppressant. Bioley G. (Clin. Cancer Res. 15: 299-306 (2009)) specific for HLA-B or HLA-C restricted peptides derived from the antigen from patients vaccinated with the cancer antigen NY-ESO-1. Cytotoxic T cells were obtained. Therefore, the soluble peptide capable of binding to the MHC class I molecule of the present invention is not only an HLA-A restricted epitope such as a peptide derived from WT-1 protein, but also an HLA-B or HLA-C restricted epitope. Also good.

  Disease-related antigens expressed by patient cells include WT-1, human telomerase reverse transcriptase (hTERT), survivin, tyrosinase, NY-ESO-1, CEA, NSE, PSA, gp100, MART-1 and MAGE-3. Including, but not limited to, tumor-associated antigens, antigens expressed in cancer cells (excessively) such as EB virus-related antigens such as EBER and LMP-1, cytomegalovirus pp65 (CMVpp65) protein, etc. And an antigen expressed in an infected cell such as a virus-specific antigen such as, but not limited to, an AIDS virus-specific antigen such as HIVgp160. Therefore, the pharmaceutical composition of the present invention may be used for cancer treatment or infectious disease treatment. Soluble peptides capable of binding to MHC class I molecules of the present invention may be epitopes of these antigens.

  The soluble peptide capable of binding to the MHC class I molecule of the present invention may consist of the same amino acid sequence as that of the natural protein or an amino acid sequence that is partially different from the amino acid of the natural protein. Alternatively, it may be a peptide containing the same amino acid sequence as that of a natural protein or an amino acid sequence that is partially different from that of a natural protein. For example, the soluble peptide includes amino acids 126 to 134 of the WT-1 protein (SEQ ID NO: 1) and amino acids 235 to 243 of the WT-1 protein. Mutant amino acid sequence (SEQ ID NO: 2) in which the 236th methionine residue is substituted with a tyrosine residue, amino acid sequence from 461st to 469th of hTERT (SEQ ID NO: 3), and survivin splicing variant It consists of an amino acid sequence selected from the group consisting of the amino acid sequence from the 80th to 88th amino acid sequence (SEQ ID NO: 4) of 2B and the amino acid sequence from 341th to 349th amino acid sequence (SEQ ID NO: 5) of CMVpp65 Alternatively, it may contain an amino acid sequence selected from the group.

  The solid-phased anti-CD28 antibody of the present invention may be any antibody having agonistic activity against CD28. For solid-phase immobilization, any solid support capable of accessing the surface of cultured CD8-positive cells and performing effective CTL induction is used. Preferred solid supports in the present invention include, but are not limited to, latex and other commercially available microparticles and culture vessels. The culture vessel includes, but is not limited to, a dish, a flask, a plate, and a multiwell plate. The anti-CD28 antibody of the present invention may be bound directly to the solid support of the present invention, or may be bound via a specific binding partner that performs a specific interaction such as avidin-biotin. In some cases, microbeads on which streptavidin is immobilized and biotinylated anti-CD28 antibody are used. The microbeads may have magnetism. Hereinafter, the anti-CD28 antibody immobilized on microbeads by specific interaction between biotin and streptavidin may be referred to as anti-CD28 immunobeads.

  The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier. Representative examples are any solution capable of suspending living cells, such as physiological saline, phosphate buffered saline (PBS), medium, serum, and the like.

The schematic diagram which shows the hypothesis regarding the action mechanism of the composition for cytotoxic T cell induction | guidance | derivation of this invention. Umbilical cord blood-derived CD8 positive cells cultured without CTL induction treatment, cells stained with fluorescein isothiocyanate (FITC) -labeled anti-CD3 antibody and allophycocyanin (APC) -labeled anti-CD8 antibody, and passed through the CD3 ⁺ gate Among these, the result figure of the two-dimensional flow cytometry analysis in which the intensity | strength in the fluorescence wavelength of PE and APC was measured. For cord blood-derived CD8 positive cells cultured without CTL induction treatment, FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer, and APC-labeled anti-CD8 antibody FIG. 3 is a diagram showing the result of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC is measured among cells that have been stained and passed through the CD3 ⁺ gate. After WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads, the cultured cord blood-derived CD8 positive cells are stained with FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody FIG. 6 is a diagram showing the results of two-dimensional flow cytometry analysis in which the intensity of PE and APC at the fluorescence wavelength is measured among cells that have passed through the CD3 ⁺ gate. After WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads, the cultured cord blood-derived CD8 positive cells were subjected to FITC-labeled anti-CD3 antibody and PE-labeled HLA-A ^* 24: Two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that were stained with 02WT-1 (mu) -tetramer and APC-labeled anti-CD8 antibody and passed through the CD3 ⁺ gate. Result diagram. FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody for umbilical cord blood-derived CD8-positive cells cultured after WT-1 peptide-specific CTL induction with WT-1 mutant peptide-added allogeneic peripheral blood-derived dendritic cells Of the two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among the cells that were stained with and passed through the CD3 ⁺ gate. WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added allogeneic peripheral blood-derived dendritic cells, followed by culture of cord blood-derived CD8 positive cells, FITC-labeled anti-CD3 antibody and PE-labeled HLA-A ^* 24: 02 WT-1 (mu) -tetramer and a two-dimensional flow in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that passed through a CD3 ⁺ gate stained with an APC-labeled anti-CD8 antibody. The result figure of cytometry analysis. After performing WT-1 peptide-specific CTL induction by dendritic cells derived from autologous cord blood monocytes derived from WT-1 mutant peptides, the cultured cord blood-derived CD8-positive cells were subjected to FITC-labeled anti-CD3 antibody and APC-labeled anti-CD3. FIG. 3 is a diagram showing the result of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC is measured among cells that have been stained with the CD8 antibody and passed through the CD3 ⁺ gate. After WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added autologous cord blood monocyte-derived dendritic cells, with respect to cultured cord blood-derived CD8-positive cells, FITC-labeled anti-CD3 antibody and PE-labeled HLA -A ^* 24: 02 WT-1 (mu) -two-dimensional stained with an APC-labeled anti-CD8 antibody and measured for the intensity at the fluorescence wavelength of PE and APC among cells passing through the CD3 ⁺ gate The result figure of a flow cytometry analysis. For umbilical cord blood-derived CD8-positive cells that have been subjected to WT-1 peptide-specific CTL induction treatment with soluble WT-1 peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody and PE-labeled HLA-A ^* 24: 02WT- Results of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that were stained with 1 (mu) -tetramer and APC-labeled anti-CD8 antibody and passed through the CD3 ⁺ gate. Figure. Umbilical cord blood-derived CD8-positive cells cultured without CTL induction treatment, stained with FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody, and of the cells passing through the CD3 ⁺ gate, fluorescence of PE and APC The result figure of the two-dimensional flow cytometry analysis in which the intensity | strength in a wavelength was measured. For cord blood-derived CD8 positive cells cultured without CTL induction treatment, FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer, and APC-labeled anti-CD8 antibody FIG. 3 is a diagram showing the result of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC is measured among cells that have been stained and passed through the CD3 ⁺ gate. For peripheral CD8-positive cells cultured after stimulation with hTERT soluble peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02hTERT-tetramer, and APC-labeled anti-CD8 antibody Of the two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among the cells that were stained with and passed through the CD3 ⁺ gate. Samples stained by mixing FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody without mixing PE-labeled hTERT peptide-tetramer, and at the fluorescence wavelength of PE and APC of cells that passed the CD3 ⁺ gate The result figure of the two-dimensional flow cytometry analysis in which intensity | strength was measured. Umbilical cord blood-derived CD8-positive cells cultured without CTL induction treatment, stained with FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody, and of the cells passing through the CD3 ⁺ gate, fluorescence of PE and APC The result figure of the two-dimensional flow cytometry analysis in which the intensity | strength in a wavelength was measured. For cord blood-derived CD8 positive cells cultured without CTL induction treatment, FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02 survivin-2B-tetramer, APC-labeled anti-CD8 antibody, FIG. 3 is a diagram showing the results of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC is measured among cells that have been stained with CD3 and passed through the CD3 ⁺ gate. After being stimulated by ^{HLA-A * 24:02 survivin-2B} AYACNTSTL soluble peptides and anti-CD28 immunobeads, the cultured peripheral blood-derived CD8-positive cells, and FITC-labeled anti-CD3 antibody, PE-labeled ^HLA-A * 24: FIG. 3 is a diagram showing the results of two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that were stained with 02hTERT-tetramer and an APC-labeled anti-CD8 antibody and passed through a CD3 ⁺ gate. PE and APC fluorescence wavelengths of cells that passed through the CD3 ⁺ gate in a sample stained by mixing FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody without mixing PE-labeled survivin-2B peptide-tetramer The result figure of the two-dimensional flow cytometry analysis in which the intensity | strength in was measured. For umbilical cord blood-derived CD8 positive cells stimulated with WT-1 mutant peptide, CMVpp65 peptide, hTERT soluble peptide, survivin-2B soluble peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody, PE-labeled HLA- A two-dimensional flow in which the intensity at the fluorescence wavelength of PE and APC was measured among the cells stained with A ^* 24: 02WT-1 (mu) -tetramer and APC-labeled anti-CD8 antibody and passed through the CD3 ⁺ gate.・ Results of cytometry analysis. For umbilical cord blood-derived CD8-positive cells stimulated with WT-1 mutant peptide, CMVpp65 peptide, hTERT soluble peptide, survivin-2B soluble peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody and PE-labeled HLA -A ^* 24: 02 Two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that were stained with ACM-labeled anti-CD8 antibody and stained with APC-labeled anti-CD8 antibody and passed through the CD3 ⁺ gate. Result diagram. For umbilical cord blood-derived CD8-positive cells stimulated with WT-1 mutant peptide, CMVpp65 peptide, hTERT soluble peptide, survivin-2B soluble peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody and PE-labeled HLA -A ^* 24: 02 hTERT-Two-dimensional flow cytometry analysis in which the intensity at the fluorescence wavelength of PE and APC was measured among the cells that passed through the CD3 ⁺ gate and stained with an anti-CD8 antibody and labeled with an anti-CD8 antibody. Result diagram. For umbilical cord blood-derived CD8-positive cells stimulated with WT-1 mutant peptide, CMVpp65 peptide, hTERT soluble peptide, survivin-2B soluble peptide and anti-CD28 immunobeads, FITC-labeled anti-CD3 antibody and PE-labeled HLA -A ^* 24: 02 Dimensional flow cytometry in which the intensity at the fluorescence wavelength of PE and APC was measured among cells that passed through the CD3 ⁺ gate after staining with 02survivin-2B-tetramer and APC-labeled anti-CD8 antibody. Analysis result diagram. Umbilical cord blood-derived CD8-positive cells of control experiments in which CTL induction was not performed were stained with FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer, and APC-labeled anti-CD8 antibody FIG. 6 is a diagram showing the results of two-dimensional flow cytometry analysis in which the intensity of PE and APC at the fluorescence wavelength is measured among cells that have passed through the CD3 ⁺ gate. Two-dimensional flow cytometry in which the intensity at the fluorescence wavelength of PE and APC of cells passing through a CD3 ⁺ gate was measured with a sample stained by mixing a FITC-labeled anti-CD3 antibody and an APC-labeled anti-CD8 antibody. Analysis result diagram.

DESCRIPTION OF SYMBOLS 1 CD8 positive cell 2 Soluble peptide 3 Solid support 4 Anti-CD28 antibody 5 CD28 molecule 6 T cell receptor / CD3 / CD8 complex 7 HLA class I molecule 8 Cell expressing HLA class I molecule 9 Restricted by HLA class I molecule 7 Cytotoxic T cells recognizing soluble peptide 2 produced

  The embodiments of the present invention described below are for illustrative purposes only and are not intended to limit the technical scope of the present invention. The technical scope of the present invention is limited only by the appended claims. Modifications of the present invention, for example, addition, deletion, and replacement of the configuration requirements of the present invention can be made on the condition that the gist of the present invention is not deviated.

WT-1 peptide-specific CTL induction from umbilical cord blood (1)
1. Materials and Methods (1) Human umbilical cord blood Human umbilical cord blood samples were collected after obtaining the informed consent signature of the mother and stored frozen in a liquid nitrogen system in RIKEN BioResource Center. Blood collection methods are described in Rubinstein, P. et al. (Blood, 81: 1679-1690 (1993)) and the cryopreservation method is described in Rubinstein, P. et al. (Proc. Natl. Acad. Sci. USA, 92: 10119-10122 (1995)).

(2) Medium and Reagent X-VIVO ™ 15 (Takara Bio Inc., Shiga) was used as the medium. In some experiments, human AB serum (Lonza, Lonza Japan Co., Ltd.) with a final concentration of 0-5% was added. Recombinant human IL-7 (Peprotech, Toyobo Co., Ltd.) and IL-15 (Peprotech, Toyobo Co., Ltd.) were added at final concentrations of 0 to 10 ng / mL and 0 to 300 ng / mL, respectively. It was done. As the soluble peptide, HLA-A ^* 24: 02WT-1 (mu) CYTWNQMNL was used. The amino acid sequence (CYTWNQMNL) of the peptide is listed as SEQ ID NO: 2 in the attached sequence listing. As the solid-phased anti-CD28 antibody, biotinylated anti-human CD28 mouse monoclonal antibody (clone CD28.2, BioLegend Japan Co., Ltd.) is a magnetic bead (Dynabeads ™ M-280 Streptavidin, Life Technologies Japan Co., Ltd.). And then incubated at room temperature for 30 minutes and then used after binding by biotin-avidin reaction. Hereinafter, the anti-CD28 antibody bound to the magnetic beads is referred to as a complex of biotinylated CD28 antibody and beads or a solid-phased anti-CD28 antibody.

(3) Purification and amplification of autologous cord blood-derived dendritic cells Umbilical cord blood obtained from RIKEN (ID number: HCB00747, HLA-A locus compatible type: 24:02 and 02:06) 25 mL is 37 ° C Were thawed in a warm water bath and suspended in PBS supplemented with 5% final concentration of dextostane 40 (Terumo Japan) and 2.5% human serum albumin (Japanese Red Cross). The obtained leukocytes were further washed 3 times with PBS supplemented with 5 mM EDTA and 2% human serum albumin. Thereafter, 25 μL of Dynal ™ immunomagnetic beads CD14 (Life Technologies Japan Co., Ltd.) per 10 ⁸ cells was added to the leukocyte suspension and stirred at room temperature of 20 ° C. for 10 minutes or more. CD14 positive cells and monocyte macrophages phagocytosed by beads were separated using a magnetic particle separator (DynaMag-15, Life Technologies Japan Co., Ltd.). The fraction of CD14 negative cells was used for purification and amplification of CD3 / CD28 positive cells as described in section (4) below. The isolated CD14-positive monocytes are suspended in X-VIVO ™ 15 medium supplemented with 5% human AB serum at a concentration of 10 ⁶ cells / mL, and a 35 mm petri dish (EZ-BindShut ™, Asahi Glass). And 50 ng / mL recombinant human granulocyte macrophage colony stimulating factor (GM-CSF, Peprotech) and 50 ng / mL recombinant human interleukin-4 (IL-4, Peprotech) Was added and cultured. On day 6 of culture, 50 ng / mL prostaglandin E2 (Daiichi Kagaku) and final concentration of 10 μg / mL picibanil (OK432, Roche Chugai) were added. The cells were further cultured for 1 day to obtain mature dendritic cells.

(4) Purification and amplification of cord blood-derived CD3 / CD28 positive cells (3) In order to further remove CD4 positive cells from the CD14 negative cell fraction separated in section 3, 25 μL Dynal (trademark) per 2 × 10 ⁷ cells ) Immunomagnetic beads CD4 (Life Technologies Japan Co., Ltd.) was added and stirred at room temperature of 20 ° C for 10 minutes or more. CD4 positive cells the magnetic particle separator after being removed using (DynaMag-15), new Dynabeads (TM), Tcell Expander CD3 / CD28 (TM, Life Technologies Japan Ltd.) is mononuclear per 10 ⁷ After adding 25 μL and stirring on ice or at 4 ° C. for 30 minutes, CD3 / CD28 positive cells were concentrated using a magnetic particle separator (DynaMag-15). The CD8 positive cells are suspended in a suspension at a concentration of 10 ⁶ cells / mL in X-VIVO ™ 15 medium supplemented with 5% human AB type serum and 300 ng / mL recombinant human IL-15 (Peprotech). It was done. The medium to which the cytokine was added was changed every 2 to 3 days after the start of the culture. At that time, the number of viable cells was measured using trypan blue staining, and a fresh medium supplemented with 300 ng / mL of IL-15 was added so that the cell concentration was 10 ⁶ cells / mL. The CD3 / CD28 positive cells were stimulated with soluble peptides and anti-CD28 immunobeads according to the procedure described below when the total number of cells reached 1 × 10 ⁶ .

  When the growth of CD3 / CD28 positive cells is fast, X-VIVO (with 5% human AB type serum and 10 ng / mL recombinant human IL-7 (Peprotech) added for the first week ( (Trademark) was cultured in 15 medium. From day 7 onward, IL-7 was switched to 300 ng / mL recombinant human IL-15 (Peprotech), and similar results were obtained even with a minimum of 19 days of culture.

(5) WT-1 peptide-specific CTL induction by soluble WT-1 peptide and solid-phased anti-CD28 antibody When the total number of CD3 / CD28 positive cells reaches 1 × 10 ⁶ cells, the initial stimulation is solid-phased Performed with anti-CD28 antibody and soluble peptide, the second stimulation was performed on day 7 from the initial stimulation. X-VIVO ™ 15 medium supplemented with 5% human AB serum and 300 ng / mL recombinant human IL-15 was added to a final concentration of 10 μg / mL soluble peptide HLA-A ^* 24: 02WT-1 (mu ) Medium supplemented with CYTWNQMNL and immobilized anti-CD28 antibody was used for CTL induction. At this time, the bead concentration was adjusted so that the ratio of the number of magnetic immunobeads to T cells was 4: 1, and the beads were diluted with the cells during the subsequent medium exchange.

(6) Amplification after WT-1 peptide-specific CTL induction For medium exchange after the CTL induction, soluble peptide, 5% human AB type serum, and 300 ng / mL recombinant human were used so that the final concentration was 10 μg / mL. X-VIVO ™ 15 medium supplemented with IL-15 was used. CTL amplification took 19 days at the shortest and 40 days at the longest.

(7) WT-1 peptide-specific CTL induction by allogeneic HLA-matched peripheral blood-derived dendritic cells (7.1) Blood collection of peripheral blood 2 healthy volunteer subjects (HLA-A locus compatible: HLA-A ^* Peripheral blood was collected from 24:02 and 02:07, HLA-A ^* 24:02 and 26:01). This experiment was approved by the Ethics Review Committee of the University of Tokyo Institute of Medical Science (approval number 20-56-0210, initial approval date: February 10, 2009, change approval date: November 19, 2010). Written consent has been obtained from the volunteer subjects. For blood collection, a vacuum blood collection tube (TERUMO Venoject II EDTA-2Na) equipped with a 21-22G needle was used.

(7.2) Preparation of dendritic cells from peripheral blood The obtained blood was diluted 2-fold with a diluent (PBS) kept at room temperature, and 20 to 35 mL of diluted blood was added to 10 to 15 mL in each centrifuge tube. Overlaid on Ficoll Paque (specific gravity 1.077, GE Healthcare Japan Co., Ltd.). Centrifugation was carried out at 500 × g for 30 minutes at room temperature and stopped without braking. The centrifugal supernatant (plasma part) was removed leaving a few mL, and the intermediate layer was recovered. The intermediate layer collected from one or two centrifuge tubes was collected in one new centrifuge tube, and the volume was adjusted to 50 mL with the diluent. The second centrifugation was performed under conditions of 500 × g and room temperature for 5 minutes. The supernatant was removed and the pellet was suspended in 30 mL of the diluent. The third centrifugation was performed under conditions of 500 × g and room temperature for 5 minutes. The supernatant was removed, and the pellet was suspended in PBS supplemented with 2 mM EDTA and 0.1% human serum albumin so that the cell concentration was 1 × 10 ⁷ cells / mL (hereinafter, “ Mononuclear cell suspension "). Dynal (trademark) immunomagnetic beads CD14 (Life Technologies Japan, Inc.) was added to the mononuclear cell suspension by 25 μL per 10 ⁸ mononuclear cells, and stirred at 4 ° C. for 30 minutes. After the reaction, CD14 positive monocytes were separated using a magnetic particle separator (DynaMag-15), and these monocytes were separated from 50 ng / mL GM-CSF, 50 ng / mL IL-4, and 5% human AB. And cultured in X-VIVO ™ 15 medium supplemented with type serum. During the culture period of 6 days, no medium was exchanged. On the sixth day of culture, 50 ng / mL prostaglandin E2 and 10 μg / mL picibanil were added, followed by further culturing for one day to obtain mature dendritic cells.

(7.3) Induction of WT-1 peptide-specific CTL by human peripheral blood-derived dendritic cells Cord blood-derived CD3 / CD28 positive cells purified and amplified by the procedure described in section (4) are 5% human AB type The cells were cultured in X-VIVO ™ 15 medium supplemented with serum and 300 ng / mL human IL-15 under conditions of 37 ° C. and 5% CO ₂ . CTL induction was performed twice: initial stimulation when the total number of cells reached 1 × 10 ⁶ and second stimulation on the seventh day after the initial stimulation. In a culture solution of mature dendritic cells derived from peripheral blood prepared by the procedure described in (7.2), 10 μg / mL soluble peptide HLA-A ^* 24: 02WT-1 (mu) CYTWNQMNL (HLA-A ^* 24 : 02 for donor) or ^{HLA-a * 02: 01WT-} 1 RMFPNAPYL ( for ^HLA-a * 02:01 donor) was added and stirred for 3 hours at 37 ° C, the peptide wherein the dendritic on the cell Of HLA class I molecules. Thereafter, the mature dendritic cells and the CD8 positive cells were mixed in a 12-well plate at a ratio of 1: 5 to 1: 6.7, and further co-cultured for 12 days after the initial stimulation.

(8) Verification of the reliability of the fluorescence-labeled tetramer reagent In order to determine the proportion of cells that recognize the WT-1 peptide antigen among the induced cytotoxic T cells, abruptly on the HLA-A ^* 24 ^: 02 molecule Beads in which four WT-1 peptide molecules comprising a mutant amino acid sequence are immobilized and fluorescently labeled with PE (hereinafter referred to as “PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer”). Was used. However, avidin is covalently bound to this bead, and the biotinylated PE-labeled WT-1 peptide tetramer is bound by a specific avidin-biotin interaction. On the other hand, the anti-CD28 antibody used for induction is also biotinylated and immobilized on avidin-bound beads. Therefore, if the immobilized anti-CD28 antibody used for induction remains in the sample of flow cytometry analysis for detection of WT-1 peptide-specific CTL, PE-labeled HLA-A ^* 24: 02WT The tetramer of PE-labeled WT-1 peptide biotinylated with a portion of the -1 (mu) -tetramer beads may be dropped and replaced with a biotinylated anti-CD28 antibody. When such omission / replacement occurs, cells expressing CD28 also react upon detection of WT-1 peptide-specific CTL. Therefore, the possibility of such dropout / replacement was verified by the following experiment.

CD3 / CD28 positive cells were obtained from 2 specimens of HLA-A ^* 24 ^: 02 positive cord blood by the procedure described in section (4). The cells were cultured for 42 days in X-VIVO ™ 15 supplemented with 1,500 IU / mL IL-2, 300 ng / mL IL-15, and 5% human AB serum. . Also, CD3 / CD28 positive cells were isolated from HLA-A ^* 0201 positive healthy volunteers according to the procedure described in section (7.3), and 300 IU / mL IL-2, 300 ng / mL IL-15, 5 The cells were cultured for 21 days in X-VIVO ™ 15 supplemented with% human AB type serum. Biotinylated anti-human CD28 mouse monoclonal antibody (clone CD28.2, BioLegend Japan Co., Ltd.) was added to the human umbilical cord blood or normal human peripheral blood-derived CD3 / CD28 positive cells at 20 μL per 10 ⁶ cells, 0 ° C to Stir at 4 ° C for 30 minutes. Thereafter, PE-labeled ^{HLA-A * 24: 02WT-} 1 (mu) CYTWNQMNL tetramer (for ^HLA-A * 24:02 donor) or, PE-labeled ^{HLA-A * 02: 01WT-} 1 RMFPNAPYL tetramer ^{(HLA-A *} 02:01 donor) was added and incubated at room temperature for 20 minutes to bind the tetramer on the T cell receptor of the cells. Thereafter, 20 μL of APC-labeled anti-mouse IgG donkey monoclonal antibody (eBioscience), which is a secondary antibody for verifying that the anti-human CD28 mouse monoclonal antibody was bound to the cell surface, was added, and 0 ° C. to 4 ° C. For 20 minutes, and the binding of biotinylated CD28 antibody on the cells was verified by flow cytometry.

(9) Detection of WT-1 peptide-specific CTL Initial stimulation when the induction of WT-1 peptide-specific CTL reaches a total cell number of 1 × 10 ⁶ in any of the three types of procedures, Umbilical cord blood-derived CD3 / CD28 positive cells that have been subjected to the second stimulation and the second stimulation on the seventh day from the first stimulation were collected on the 12th day after the initial stimulation, and the FITC-labeled anti-human CD3 monoclonal mouse IgG2a antibody (clone HIT3a, BioLegend Japan Co., Ltd.), APC-labeled anti-CD8 antibody, and PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer were subjected to triple staining, and flow cytometry analysis was performed.

2. Results FIG. 2A to FIG. 2H show the initial stimulation at the stage when the total number of cells reached 1 × 10 ⁶ in any of the three types of procedures, the second stimulation on the seventh day from the initial stimulation, and the two WT−. Among the cord blood-derived CD8 positive cells subjected to the induction treatment of 1 peptide-specific CTL, HLA-A ^* 24: 02WT-1 (mu) − of the cells that passed the CD3 ⁺ gate on the 12th day after the initial stimulation. It is a result figure of the two-dimensional flow cytometry analysis of the cell which recognizes a tetramer specifically (henceforth "tetramer positive cell"). 2A to H, the vertical axis represents the fluorescence intensity of the PE label, and the horizontal axis represents the fluorescence intensity of the APC label. The samples of FIGS. 2A and 2B are X-VIVO ™ 15 medium supplemented with 5% human AB type serum and 300 ng / mL recombinant human IL-15 without any of the above three induction treatments. The cord blood-derived CD8-positive cells cultured for the same number of days as in the experiments of FIGS. 2C and 2D with medium exchange alone. The samples of FIGS. 2C and D show WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads at the stage when the total number of cells reached 1 × 10 ⁶ , and 7 It is umbilical cord blood-derived CD8 positive cells cultured until the 12th day after the first stimulation after being performed twice with the second stimulation on the day. FIGS. 2E and 2F show WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added allogeneic peripheral blood-derived dendritic cells at the stage when the total number of cells reached 1 × 10 ⁶ , and after initial stimulation It is umbilical cord blood-derived CD8-positive cells cultured twice after the second stimulation on the seventh day and then until the 12th day after the first stimulation. FIGS. 2G and 2H show initial stimulation at the stage when WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added autologous cord blood monocyte-derived dendritic cells reaches a total cell number of 1 × 10 ⁶ , The cord blood-derived CD8-positive cells cultured twice after the second stimulation on the seventh day after stimulation and then cultured until the 12th day after the first stimulation. 2A, C, E and G result samples were stained by mixing FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody. 2B, D, F, and H are obtained by mixing FITC-labeled anti-CD3 antibody, APC-labeled anti-CD8 antibody, and PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer. Stained.

As shown in FIG. 2D, soluble WT-1 peptides and anti-CD28 immunobead by WT-1 peptide-specific CTL induced from umbilical cord blood that has been subjected to CD3 / CD28 positive about 8 cells passing through the CD3 ⁺ gate of the cell. 21% specifically recognized tetramer positive, ie, WT-1-derived peptides that are cancer antigens in the context of HLA-A ^* 24 ^: 02 allele. WT-1-specific cytotoxic T cells are known to react with lymphoma and other malignant cells that overexpress WT-1, but do not attack normal cells that express only a relatively small amount of WT-1. (Gao, L. et al., Blood, 95: 2198-2203 (2000), Oka, Y. et al., Curr. Op. In Immunol., 20: 211-220 (2008)). In contrast, as shown in FIG. 2F, umbilical cord blood-derived CD8 positive cells subjected to WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added allogeneic peripheral blood-derived dendritic cells passed through the CD3 ⁺ gate. only about 0.22% of the cells, ^HLA-a * 24:02 allyl context in cancer antigen is a peptide ^{HLA-a * 24: 02WT-} 1 (mu) did not specifically recognize the CYTWNQMNL. Further, as shown in FIG. 2H, among umbilical cord blood-derived CD3 positive cells subjected to WT-1 peptide-specific CTL induction by WT-1 mutant peptide-added autologous cord blood monocyte-derived dendritic cells, the CD3 ⁺ gate was passed. only about 0.55% of the cells, ^HLA-a * 24:02 allyl context in cancer antigen is a peptide ^{HLA-a * 24: 02WT-} 1 (mu) did not specifically recognize the CYTWNQMNL. In addition, as shown in FIG. 2B, in the cord blood-derived CD8 positive cells of the control experiment in which WT-1 peptide-specific CTL induction was not performed, only about 1.28% of the cells that passed the CD3 ⁺ gate were HLA-A. ^* Peptide HLA-A which is a cancer antigen in the context of 24:02 allele ^* 24: 02WT-1 (mu) CYTWNQMNL was not specifically recognized. As shown in the results of FIGS. 2A, 2C, 2E, and 2G, the sample stained without being mixed with PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer and mixed with only the APC-labeled anti-CD8 antibody. Then, among the cells that passed through the CD3 ⁺ gate, the number of cells exhibiting fluorescence at the emission wavelength of PE was 0.1% or less. As described above, from the results of FIGS. 2A to 2H, among the three types of WT-1 peptide-specific CTL induction treatments, the WT-1 peptide-specific CTL induction treatment with soluble WT-1 peptide and anti-CD28 immunobeads is as follows. Compared to the induction treatment using the other two types of dendritic cells, CTLs that recognize the WT-1 peptide were induced much more. As a result of the experiment of (8), tetramer positive cells do not appear whether or not biotinylated CD28 antibody is added, and the possibility that the tetramer becomes false positive due to debiotin-avidin binding is extremely low. Was confirmed.

WT-1 peptide-specific CTL induction from umbilical cord blood (2)
1. Materials and Methods CD8 positive cells derived from umbilical cord blood (ID number: HCB00751, HLA-A locus compatible type: 24:02 and 33:03) different from Example 1 were subjected to the same three types of induction treatment as in Example 1. And subjected to flow cytometry analysis of tetramer positive cells.

2. Results FIG. 3 shows the initial stimulation when the total number of cells reached 1 × 10 ⁶ with soluble WT-1 peptide and anti-CD28 immunobeads, the second stimulation on the seventh day from the initial stimulation, and the two WT- Results of two-dimensional flow cytometry analysis of tetramer positive cells out of cells that passed the CD3 ⁺ gate on the 12th day after initial stimulation for cord blood-derived CD8 positive cells subjected to the induction treatment of 1 peptide-specific CTL FIG. The vertical axis of the result diagram of FIG. 3 is the fluorescence intensity of the PE label, and the horizontal axis is the fluorescence intensity of the APC label. The sample of FIG. 3 shows WT-1 peptide-specific CTL induction by soluble WT-1 peptide and anti-CD28 immunobeads at the stage when the total number of cells reached 1 × 10 ⁶ cells, and 7 days after the initial stimulation. Umbilical cord blood-derived CD8-positive cells cultured until the 12th day after the first stimulation after the second stimulation with FITC-labeled anti-CD3 antibody, APC-labeled anti-CD8 antibody, and PE-labeled HLA- A ^* 24: 02WT-1 (mu) -tetramer was mixed and stained.

As shown in FIG. 3, umbilical cord blood-derived CD3 / CD28 that was subjected to WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads even in cord blood-derived CD8 positive cells different from Example 1. About 9.43% of the positive cells that passed the CD3 ⁺ gate were tetramer positive. In contrast, for the same umbilical cord blood, WT-1 peptide-specific CTL induction by autologous cord blood-derived dendritic cells and WT-1 peptide-specific CTL induction by allogeneic HLA-matched peripheral blood-derived dendritic cells And the tetramer positive cells among the cells that passed through the CD3 ⁺ gate were 0.36% and 0.33%, respectively (not shown). In umbilical cord blood-derived CD3 / CD28 positive cells in a control experiment in which WT-1 peptide-specific CTL induction was not performed, only about 0.52% of the cells that passed the CD3 ⁺ gate were HLA-A ^* 24 ^: 02 allyl. WT-1-derived peptides that are cancer antigens in context were not specifically recognized. Samples stained by mixing FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody without mixing PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer passed through the CD3 ⁺ gate. Among the cells, the number of cells exhibiting fluorescence at the fluorescence wavelength of PE was 0.05% or less.

From the above results, in experiments using a plurality of umbilical cord blood, the WT-1 peptide-specific CTL induction treatment with soluble WT-1 peptide and anti-CD28 immunobeads is more WT- It has been shown to induce much more CTLs that recognize one peptide. In clinical trials of cancer therapy using peptide vaccines, the ratio of tetramer positive cells when vaccine sensitization is performed in a patient is reported. For example, according to the report of Oka Y et al. (Proc Natl Acad Sci USA, 101: 13885 (2004)), wild type or mutant type HLA-A was detected against 2 breast cancers, 10 lung cancers, 14 leukemias and the like. ^{* When} 24:02 restricted WT-1 peptide (0.3 mg-30 mg) was sensitized three times at 2 week intervals with Freund's incomplete adjuvant, the ratio of WT-1 tetramer positive CD8 positive cells before sensitization was centered The value was 0.245% (range: 0.08-1.21%), and the ratio of WT-1 tetramer positive CD8 positive cells after sensitization was median 0.34% (range 0.11-6.61%) )Met. According to a report of Van Tendeloo VF et al. (Proc Natl Acad Sci USA, 107: 13824 (2010)), an autologous dendritic tree in which mRNA of WT-1 protein was introduced into a patient in remission phase acute myeloid leukemia (AML). In clinical trials where cells were inoculated subcutaneously, less than 1% tetramer positive cells were detected in peripheral blood. There were no reports that clearly demonstrated the proportion of tetramer positive cells in in vitro sensitization experiments using peptide antigens restricted with HLA class I molecules.

Single CTL induction from cord blood Materials and Methods According to the procedure described in Example 1, different umbilical cord blood that was confirmed to be HLA-A ^* 24: 02 positive (ID number: HCB00756, HLA-A locus adapted type: 24:02) And 33:03), CD14 negative CD4 negative CD3 / CD28 positive cells were isolated. The cells are amplified for the first week at 37 ° C., 5% CO ₂ in X-VIVO ™ 15 medium supplemented with 10 ng / mL IL-7 and 5% human type AB serum, Then, once every 2-3 days, X-VIVO ™ 15 medium supplemented with 300 ng / mL IL-15 and 5% human AB type serum has an optimal cell concentration of 10 ⁶ cells / mL. Each was added and amplified for another 28 days. Thereafter, the cells were suspended in Cell Banker (trademark) (Juji Field Co., Ltd.), stored frozen in liquid nitrogen, thawed at the time of use, and used for the following experiments. X-VIVO ™ 15 medium supplemented with 5% human type AB serum and 300 ng / mL IL-15, a complex of biotinylated CD28 antibody and beads, and cancer antigen WT-1 specific CD3 / CD28 thawed in a medium supplemented with genetically mutated soluble peptide HLA-A ^* 24: 02WT-1 (mu) CYTWNQMNL or CMVpp65 specific peptide HLA-A ^* 24: 02CMVpp65 QYDPVAALF (SEQ ID NO: 5) Positive cells were cultured for 10 days. The cells on day 10 is recovered in PBS, PE-labeled ^{HLA-A * 24: 02WT-} 1 (mu) CYTWNQMNL or tetramer, PE-labeled ^HLA-A * 24: 02CMVpp65 QYDPVAALF tetramer or not ¹⁰⁶ cells per 20μL added After standing for 20 minutes at room temperature, FITC-labeled anti-human CD3 monoclonal mouse IgG2a antibody (clone HIT3a, BioLegend Japan) and APC-labeled anti-CD8 antibody (clone RPA-T8, BioLegend Japan) 20 μL each was added and stirred at 0 ° C. to 4 ° C. for 20 minutes before being subjected to flow cytometry analysis.

2. Results As a result of the same flow cytometry analysis as in Examples 1 and 2, umbilical cord blood-derived CD8 positive cells frozen once after the initial culture were prepared at the stage where the total number of cells was adjusted to 1 × 10 ⁶ after re-thawing. In a medium supplemented with cancer antigen WT-1 specific mutant soluble peptide HLA-A ^* 24: 02WT-1 (mu) CYTWNQMNL or CMVpp65 specific soluble peptide HLA-A ^* 24: 02QYDPVAALF and CD28 immunobeads Among the cells cultured after the first stimulation and until the 10th day after the stimulation, about 2.72% of the cells that passed through the CD3 ⁺ gate were WT-1 peptide tetramer positive cells (not shown) ). Similarly, for cells cultured until 10 days after stimulation after stimulation with a medium supplemented with CMVpp65-specific soluble peptide HLA-A ^* 24: 02QYDPVAALF and CD28 immunobeads, CD3 ⁺ gate Among the cells that passed through, CMVpp65 peptide tetramer positive cells were about 3.39% (not shown). In a sample in which cord blood-derived CD3 positive cells in a control experiment in which peptide-specific CTL induction was not performed were stained by mixing PE-labeled WT-1 peptide tetramer and PE-labeled CMVpp65 peptide tetramer, a CD3 ⁺ gate was used. Among the cells that passed through, 0.77% of the cells showed fluorescence at the fluorescence wavelength of PE (not shown). In samples in which umbilical cord blood-derived CD3 positive cells subjected to WT-1 peptide-specific CTL induction were mixed with only APC-labeled anti-CD8 antibody without mixing PE-labeled WT-1 peptide tetramer, CD3 ⁺ Among the cells that passed through the gate, 0.19% of the cells showed fluorescence at the fluorescence wavelength of PE (not shown). Cord blood-derived CD3 positive cells subjected to CMVpp65 peptide-specific CTL induction passed through CD3 ⁺ gate in samples stained with only APC-labeled anti-CD8 antibody without mixing PE-labeled CMVpp65 peptide tetramer Among the cells, 0.27% showed fluorescence at the fluorescence wavelength of PE (not shown). Umbilical cord blood-derived CD3 positive cells in a control experiment in which peptide-specific CTL induction was not performed were mixed with only APC-labeled anti-CD8 antibody without mixing PE-labeled WT-1 peptide tetramer or PE-labeled CMVpp65 peptide tetramer. Of the cells that passed through the CD3 ⁺ gate, 0.14% of the cells showed fluorescence at the fluorescence wavelength of PE (not shown).

  The results of this example showed that the treatment process of WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads is effective only once. In addition, peptide-specific CTL induction by a soluble peptide and anti-CD28 immunobeads is not limited to the WT-1 peptide, and it was shown that CMVpp65 peptide is also effective. Therefore, it is suggested that the peptide-specific CTL induction method of the present invention using a soluble peptide and anti-CD28 immunobeads in combination can be carried out regardless of the type of peptide antigen. If the amino acid sequence of a peptide presented as an antigen is determined according to the HLA compatible type of the patient, this treatment induces many cytotoxic T cells regardless of whether they are tumor antigens or viral antigens. It is possible to do. In addition, by using a soluble peptide as a peptide antigen, the antigen can be easily changed even when tumor cells or viruses are mutated to cause an escape mutation that acquires vaccine resistance. In addition, in this example, since CTL induction was effective once, it can be expected that it can be performed with a simpler culture protocol than the conventional CTL induction method.

WT-1 peptide-specific CTL induction from peripheral blood Materials and Methods Peripheral blood was collected from the same healthy volunteer subjects as in Example 1 (7.1) (HLA-A locus adapted: HLA-A ^* 24:02 and 26:01). Blood was collected in the same procedure as in Example 1 (7.1), a mononuclear cell suspension was prepared in the same procedure as in Example 1 (7.2), and CD14 positive monocytes were removed from the mononuclear cell suspension. It was. CD8 positive cells were purified from the remaining CD14 negative fraction using a flow comp CD8 kit (Life Technologies Japan). Specifically, biotinylated anti-CD8 antibody and human peripheral blood mononuclear cell suspension CD14 negative fraction were reacted on ice (0 ° C. to 4 ° C.) for 10 minutes, and then avidin-coupled magnetic immunobeads and ice on the ice. The reaction was performed at (0 ° C. to 4 ° C.) for 15 minutes, and CD8 positive cells were separated using a magnetic particle separator (DynaMag-15). Thereafter, a release buffer was added at room temperature and incubated for 10 minutes to release the avidin-conjugated magnetic immunobeads from CD8 positive lymphocytes. The recovered CD8-positive cells were cultured in X-VIVO ™ 15 medium supplemented with 5% human AB type serum and 300 ng / mL IL-15 at 37 ° C. and 5% CO ₂ . After preparation the total cell number 1 × 10 ⁶ cells, cancer antigen WT-1 mutagenesis soluble peptides ^{HLA-A * 24: 02WT-} 1 (mu) CYTWNQMNL or, whether CMVpp65-specific peptides ^HLA-A * 24:02 QYDPVAALF First stimulation was performed in a medium supplemented with CD28 immunobeads, and the same stimulation was performed on the 7th day after the initial stimulation, and the culture was continued until the 11th day after the initial stimulation. Every 2-3 days, the cells were diluted with fresh medium supplemented with IL-15 to a cell concentration of 10 ⁶ cells / mL. On the 11th day after the initial stimulation, the tetramer positive rate was analyzed by flow cytometry.

2. Results As a result of the same flow cytometry analysis as in Examples 1 to 3, the cancer antigen WT-1-specific mutant soluble peptide HLA-A ^* 24: 02WT-1 (mu) CYTWNQMNL and CD28 immunobead were added to the medium. When the total number of cells reaches 1 × 10 ⁶ , the initial stimulation is performed, and the same stimulation is performed on the 7th day after the initial stimulation, and then the peptide-specific CTL induction treatment is performed until the 11th day after the initial stimulation. Among the peripheral blood-derived CD8-positive cells, WT-1 peptide tetramer-positive cells accounted for about 5.13% of the cells that passed the CD3 ⁺ gate on the 11th day from the start of culture (not shown). Among the peripheral blood-derived CD3 positive cells in the control experiment in which peptide-specific CTL induction was not performed, about 0.15% of the WT-1 peptide tetramer positive cells out of the cells that passed the CD3 ⁺ gate on the 11th day of culture start (Not shown). Similarly, when peripheral blood-derived CD8-positive cells were stimulated twice with the CMVpp65 soluble peptide and anti-CD28 immunobeads on the first day of culture and the seventh day, cells that passed the CD3 ⁺ gate on the first day of culture Among them, WT-1 peptide tetramer positive cells were about 4.53% (not shown). In the sample stained by mixing the FITC-labeled anti-CD3 antibody and the APC-labeled anti-CD8 antibody without mixing the PE-labeled WT-1 peptide-tetramer, the fluorescence wavelength of PE among the cells that passed through the CD3 ⁺ gate The number of cells exhibiting fluorescence was 0.13% or less (not shown).

Human telomerase hTERT-derived peptide-specific CTL induction from umbilical cord blood Materials and Methods From different umbilical cord blood (ID numbers: HCB01100, HLA-A locus adapted types: 24:02 and 26:01) that could be confirmed to be HLA-A ^* 24: 02 positive, Example 1 ( According to the procedure described in 3), CD14 negative CD4 negative CD3 / CD28 positive cells were separated using magnetic immunobeads. The cells were diluted to a concentration of 10 ⁶ cells / mL, 37 ° C, 5 ° C. in X-VIVO ™ 15 medium supplemented with 10 ng / mL IL-7 and 5% human type AB serum. In X-VIVO ™ 15 medium supplemented with 300 ng / mL IL-15 and 5% human AB type serum from the 7th day after amplification for the first week after the start of culture at% CO ₂ concentration, The cells were diluted once every 2-3 days so that the optimal cell concentration was 10 ⁶ cells / mL. When the total number of cells reaches 1 × 10 ⁶ , initial stimulation is performed with a medium supplemented with hTERT-derived soluble peptide HLA-A ^* 24: 02 VYGFVRACL (SEQ ID NO: 3) and CD28 immunobeads, and 7 days after the initial stimulation. After similar stimulation to the eyes, the cells were cultured until the 14th day after the initial stimulation. At the time of stimulation, the complex of biotinylated CD28 antibody and beads was added at a bead: cell ratio of 4: 1. Cells were harvested with PBS on day 14 post-priming, PE-labeled ^HLA-A * 24 of 10 ⁶ cells per 20μL: 02hTERT VYGFVRACL tetramer is added, after being allowed to stand at room temperature for 20 minutes, FITC-labeled anti-human 20 μL each of CD3 monoclonal mouse IgG2a antibody (clone HIT3a, BioLegend Japan) and APC-labeled anti-CD8 antibody (clone RPA-T8, BioLegend Japan) were added and stirred at 0 ° C. to 4 ° C. for 20 minutes. And subjected to flow cytometry analysis.

2. Results FIGS. 4A to 4D are results of two-dimensional flow cytometry analysis using FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02hTERT VYGFVRACL tetramer, and APC-labeled human anti-CD8 antibody. 4A to 4D, the vertical axis represents the fluorescence intensity of the PE label, and the horizontal axis represents the fluorescence intensity of the APC label. CD8-positive cord-derived CD8-positive cells treated with hTERT-derived peptide-specific CTL in a medium supplemented with hTERT-soluble peptide HLA-A ^* 24: 02VYGFVRRACL and CD28 immunobeads on day 14 after initial stimulation Among the cells that passed through the ⁺ gate, hTERT peptide tetramer positive cells were about 0.74% (FIG. 4C). Among the cord blood-derived CD3 positive cells in the control experiment in which peptide-specific CTL induction was not performed, of the cells that passed the CD3 ⁺ gate on the 11th day of the start of culture, hTERT peptide tetramer positive cells were about 0.06%. (FIG. 4B). PE-labeled hTERT peptide-tetramer is not mixed with cord blood-derived CD8-positive cells that have been subjected to induction of hTERT-derived peptide-specific CTL in a medium supplemented with hTERT-soluble peptide HLA-A ^* 24: 02VYGFVRRACL and CD28 immunobeads In the sample stained with the mixture of the FITC-labeled anti-CD3 antibody and the APC-labeled anti-CD8 antibody, among the cells that passed through the CD3 ⁺ gate, 0.08 cells showed fluorescence at the emission wavelength of PE. % Or less (FIG. 4D). In cord blood-derived CD3-positive cells of a control experiment in which peptide-specific CTL induction was not performed, a sample stained with FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody without mixing PE-labeled hTERT peptide-tetramer Among the cells that passed through the CD3 ⁺ gate, 0.02% of the cells showed fluorescence at the fluorescence wavelength of PE (FIG. 4A).

Induction of survivin-2B-specific peptide-specific CTL from umbilical cord blood Materials and Methods From different umbilical cord blood (ID numbers: HCB01100, HLA-A locus adapted types: 24:02 and 26:01) that could be confirmed to be HLA-A ^* 24: 02 positive, Example 1 ( According to the procedure described in 3), CD14 negative CD4 negative CD3 / CD28 positive cells were separated using magnetic immunobeads. The cells were diluted to a concentration of 10 ⁶ cells / mL, 37 ° C., 5% in X-VIVO ™ 15 medium supplemented with 10 ng / mL IL-7 and 5% human AB serum. From the 7th day, the X-VIVO ™ 15 medium supplemented with 300 ng / mL IL-15 and 5% human AB serum was amplified for the first week after the start of culture at the CO ₂ concentration. It diluted once every 2-3 days so that it might become a suitable cell density | concentration of 10 < ⁶ > cells / mL. When the total number of cells reaches 1 × 10 ⁶ , first stimulation is performed with a medium supplemented with survivin-2B-derived soluble peptide HLA-A ^* 24: 02 survivin-2B AYACNTSTL (SEQ ID NO: 4) and CD28 immunobeads, The same stimulation was performed on the 7th day after the initial stimulation, and then cultured until the 10th day after the initial stimulation. At the time of stimulation, a complex of biotinylated CD28 antibody and beads was added at a bead: cell ratio of 4: 1. After the cells 10 days after stimulation recovered in PBS, PE-labeled ^{HLA-A * 24:02 survivin-2B} AYACNTSTL tetramer ¹⁰⁶ cells per 20μL was added and allowed to stand at room temperature for 20 minutes, FITC 20 μL of labeled anti-human CD3 monoclonal mouse IgG2a antibody (clone HIT3a, BioLegend Japan) and APC-labeled anti-CD8 antibody (clone RPA-T8, BioLegend Japan) were added at 0 ° C to 4 ° C. Stirred for 20 minutes and subjected to flow cytometry analysis.

2. Results FIGS. 5A to 5D show that among the cells stained with FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02 survivin-2B AYACNTSTL tetramer and APC-labeled anti-CD8 antibody and passed through the CD3 ⁺ gate, PE and It is a result figure of the two-dimensional flow cytometry analysis by APC. 5A to 5D, the vertical axis represents the fluorescence intensity of the PE label, and the horizontal axis represents the fluorescence intensity of the APC label. HLA-A ^* 24: 02 survivin-2B AYACNTSTL soluble peptide and anti-CD28 immunobeads were used for initial stimulation when the total number of cells reached 1 × 10 ⁶ , and after the same stimulation on the 7th day after the initial stimulation The cord blood-derived CD8 positive cells cultured until the 10th day after the initial stimulation were stained with FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02hTERT-tetramer, and APC-labeled anti-CD8 antibody, and CD3 ⁺ Among the cells that passed through the gate, survivin-2B peptide tetramer positive cells were about 1.16% (FIG. 5C). In the sample stained with FITC-labeled anti-CD3 antibody and APC-labeled anti-CD8 antibody without mixing PE-labeled survivin-2B peptide-tetramer, the fluorescence at the fluorescence wavelength of PE among the cells that passed through the CD3 ⁺ gate Was 0.00% or less (FIG. 5D). In the cord blood-derived CD3 positive cells of the control experiment in which peptide-specific CTL induction was not performed, among survivin-2B peptide tetramer positive cells among the cells that passed the CD3 ⁺ gate on the 10th day of culture, about 0.03% (FIG. 5B). In the sample stained by mixing the FITC-labeled anti-CD3 antibody and the APC-labeled anti-CD8 antibody without mixing the PE-labeled survivin-2B peptide-tetramer, the fluorescence wavelength of PE among the cells that passed through the CD3 ⁺ gate The number of cells exhibiting fluorescence was 0.03% (FIG. 5A).

Simultaneous induction of CTL specific for four peptides from cord blood Materials and Methods Single from different umbilical cord blood (ID number: RC2R10010, compatible type of HLA-A locus: 24: 02 / blank probably 24:02 homozygote) that could be confirmed positive for HLA-A ^* 24: 02 After the spheres were removed by the sticking method, CD4 negative CD8 positive cells were separated using magnetic immunobeads according to the procedure described in Example 1. The cells were cultured in X-VIVO ™ 15 medium supplemented with 300 ng / mL IL-15 and 5% human AB type serum at a concentration of 10 ⁶ cells / mL, and the total number of cells was 1 × 10 ⁶ cells. After the preparation, priming was performed in a medium supplemented with the following four peptides restricted to HLA-A ^* 24 ^: 02 and CD28 immunobeads. The added peptides were (1) WT-1-specific mutant peptide CYTWNQMNL, (2) CMVpp65 peptide QYDPVAALF, (3) hTERT-specific peptide VYGFVRACL, and (4) survivin-2B-specific peptide AYACNTSTL. Met. Furthermore, after the same stimulation was performed on the 7th day after the initial stimulation, the cells were cultured until the 12th day after the initial stimulation. At the time of stimulation, in addition to the peptide, a complex of biotinylated CD28 antibody and beads was added at a concentration of 4: 1 bead: cell ratio. The cells were cultured and amplified for 12 days from the initial stimulation while being diluted once every 2 to 3 days so that the optimal cell concentration was 10 ⁶ cells / mL.

On day 12, the cells were collected in PBS and either PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer, PE-labeled HLA-A ^* 24: 02CMVpp65 tetramer, or PE-labeled HLA-A ^* 24: 02hTERT or tetramer, PE-labeled ^{HLA-A * 24: 02survivin-} 2B or tetramer, are added cells 10 per ^six 20 [mu] L, after being allowed to stand at room temperature for 20 minutes, FITC-labeled anti-human CD3 monoclonal mouse IgG2a antibody (clone HIT3a BioLegend Japan Co., Ltd.) and APC-labeled anti-CD8 antibody (clone RPA-T8, BioLegend Japan Co., Ltd.) were added in an amount of 20 μL each and stirred at 0 ° C. to 4 ° C. for 20 minutes for flow cytometry analysis. It was done.

2. Results FIGS. 6A to 6D show cells stained with FITC-labeled anti-CD3 antibody, PE-labeled HLA-A ^* 24: 02WT-1 (mu) -tetramer, and APC-labeled anti-CD8 antibody, and passed through the CD3 ⁺ gate. Among these, it is a result figure of the two-dimensional flow cytometry analysis by PE and APC. 6A to 6D, the vertical axis represents the fluorescence intensity of the PE label, and the horizontal axis represents the fluorescence intensity of the APC label. After the total number of cells is adjusted to 1 × 10 ⁶ , priming is performed with WT-1-specific mutant peptide CYTWNQMNL and anti-CD28 immunobeads, and the same stimulation is performed on the 7th day after the priming, Umbilical cord blood-derived CD8-positive cells cultured until the 12th day after the initial stimulation were stained with FITC-labeled anti-CD3 antibody-derived PE-labeled HLA-A ^* WT-1-tetramer and APC-labeled anti-CD8 antibody. . Among the cells that passed the CD3 ⁺ gate, WT-1 peptide-specific tetramer positive cells accounted for about 0.89% (FIG. 6A). For umbilical cord blood-derived CD8-positive cells cultured and stained with HLA-A ^* 24: 02 CMVpp65 peptide and anti-CD28 immunobeads for the same number of days as in the experiment of FIG. 6A, cells that passed the CD3 ⁺ gate on day 12 after the initial stimulation Among them, CMVpp65-specific tetramer positive cells were about 0.66% (FIG. 6B). For cord blood-derived CD8 positive cells cultured and stained for the same number of days as in the experiment of FIG. 6A with hTERT-derived peptides and anti-CD28 immunobeads, hTERT-specific cells out of the cells that passed the CD3 ⁺ gate on day 12 after initial stimulation Tetramer positive cells were about 0.95% (FIG. 6C). The same number of days culture as experiment of FIG. 6A by survivin-2B-derived soluble peptides and anti-CD28 immunobeads, the stained cord peripheral blood-derived CD8-positive cells among the cells that has passed through the CD3 ⁺ gate 12 days after the beginning of culture, survivin-2B-specific tetramer positive cells were about 1.19% (FIG. 6D). The cord blood-derived CD8-positive cells cultured for the same number of days as in the experiments of FIGS. 6A to 6D without being subjected to peptide-specific CTL induction treatment were used for cells that passed the CD3 ⁺ gate on the 12th day after the initial stimulation. Among them, WT1 peptide-specific tetramer positive cells were about 0.58% (FIG. 6E). In the sample stained by mixing the FITC-labeled anti-CD3 antibody and the APC-labeled anti-CD8 antibody without mixing the PE-labeled peptide-tetramer, among the cells that passed through the CD3 ⁺ gate, the fluorescence at the emission wavelength of PE Was 0.05% (FIG. 6F).

  From the results of Examples, WT-1 peptide-specific CTL induction with soluble WT-1 peptide and anti-CD28 immunobeads is applicable not only to CD8-positive cells derived from cord blood but also to CD8-positive cells derived from at least peripheral blood. It has been shown. Similarly, it was shown that WT-1 peptide-specific CTL induction by soluble CMVpp65 peptide and anti-CD28 immunobeads can be applied not only to CD8-positive cells derived from cord blood but also to CD8-positive cells derived from at least peripheral blood. Furthermore, this technique is not limited to WT-1 and CMVpp65, and it has been shown that this technique can be used for a wide variety of other cancer antigens such as hTERT and survivin-2B. Thus, it is suggested that the composition for inducing cytotoxic T cells of the present invention using a soluble peptide and an immobilized anti-CD28 antibody in combination is applicable to any hematopoietic stem cell-derived CD8-positive cell. Then, the composition for inducing cytotoxic T cells of the present invention can be used for in vivo hematopoietic stem cells other than peripheral blood, for example, CD8 positive cells derived from bone marrow, lymph node and other tissue-derived hematopoietic stem cells, embryonic stem cells, It can also be applied to CD8 positive cells derived from hematopoietic stem cells differentiated from adult stem cells and induced pluripotent stem (iPS) cells.

Claims (7)

(1) extracting and culturing cells of the CD8 positive fraction from the collected umbilical cord blood or the collected peripheral blood; and
(2) exposing the cells of the CD8 positive fraction to a solid support on which an anti-CD28 antibody is immobilized and a soluble peptide capable of binding to MHC class I molecules ;
(3) A method for producing a pharmaceutical composition containing cytotoxic T cells, comprising culturing cytotoxic T cells that recognize soluble peptides capable of binding to the MHC class I molecule. The method of claim 1, comprising:
The solid support is a microbead or a cell culture vessel,
Way . The method according to claim 1 or 2, wherein
The soluble peptide capable of binding to the MHC class I molecule is presented as an antigen by an HLA-compatible HLA complex of cells of the CD8 positive fraction, and is recognized by the cytotoxic T cell, Way . A method for producing a pharmaceutical composition for treating tumors, comprising:
Comprising the method of claim 3,
The soluble peptide capable of binding to the MHC class I molecule includes a part of an amino acid sequence of a specific antigen protein of a tumor cell, and the cytotoxic T cell recognizes the tumor cell,
Way . The method of claim 4, comprising:
The specific antigen protein of the tumor cell is WT-1
Way . A method for producing a pharmaceutical composition for the treatment of viral diseases,
Comprising the method of claim 3,
The soluble peptide capable of binding to the MHC class I molecule contains a part of an amino acid sequence of a virus-specific antigen protein, and the cytotoxic T cell recognizes the virus-infected cell,
Way . The method of claim 6, comprising:
The specific antigen protein of the virus is a pp65 protein of cytomegalovirus,
Way .